535 active trials 272 recruiting 27 Phase 3 354 sponsors 66 changes in 30 days
| Early Phase 1 | 6 | |
| Phase 1 | 21 | |
| Phase 1/2 | 22 | |
| Phase 2 | 67 | |
| Phase 2/3 | 6 | |
| Phase 3 | 21 | |
| Phase 4 | 10 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT05761015 | Helping Osteoarthritis Patients to Walk With NSAID | University Hospital, Clermont-Ferrand | Recruiting | 2026-02-27 |
| NCT05005793 | Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients | University of Colorado, Denver | Recruiting | 2025-05-29 |
| NCT04957329 | Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on… | Rigshospitalet, Denmark | Recruiting | 2023-11-18 |
| NCT07674368 | Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed | Hunan Cancer Hospital | Not Yet Recruiting | 2026-07-01 |
| NCT07671560 | Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant… | Qiming Wang | Not Yet Recruiting | 2026-06-26 |
| NCT02584933 | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib… | Novartis Pharmaceuticals | Active, Not Recruiting | 2026-06-11 |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | Guangdong Association of Clinical Trials | Active, Not Recruiting | 2026-04-09 |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance… | The First Affiliated Hospital of Guangzhou Medical University | Not Yet Recruiting | 2025-03-25 |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable… | Fujian Medical University Union Hospital | Not Yet Recruiting | 2025-01-21 |
| NCT03888820 | Biofreeze® vs. a Placebo on Chronic Low Back Pain Walking Gait Characteristics and Pain | Sport and Spine Rehab Clinical Research Foundation | Active, Not Recruiting | 2019-03-25 |
| Phase 3 | ||||
| NCT07419334 | Study of ALK-001 on the Progression of Stargardt Disease | Alkeus Pharmaceuticals, Inc. | Recruiting | 2026-08-26 |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Nuvalent Inc. | Recruiting | 2026-08-25 |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells… | Eastern Cooperative Oncology Group | Recruiting | 2026-08-19 |
| NCT07455383 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | Alkermes, Inc. | Recruiting | 2026-08-07 |
| NCT07502443 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | Alkermes, Inc. | Recruiting | 2026-08-07 |
| NCT07540897 | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With… | Alkermes, Inc. | Recruiting | 2026-08-07 |
| NCT06032065 | SMART Exercise for PAD | Northwestern University | Recruiting | 2026-04-15 |
| NCT06760546 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of… | Rhythm Pharmaceuticals, Inc. | Recruiting | 2026-02-12 |
| NCT05991908 | Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating… | Shanghai Jiao Tong University School of Medicine | Recruiting | 2025-02-18 |
| NCT06643416 | Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia | Queen Mary Hospital, Hong Kong | Recruiting | 2024-10-18 |
| NCT06623123 | Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard… | East and North Hertfordshire NHS Trust | Recruiting | 2024-10-02 |
| NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small… | Betta Pharmaceuticals Co., Ltd. | Recruiting | 2024-08-23 |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in… | Hoffmann-La Roche | Active, Not Recruiting | 2026-07-15 |
| NCT07645248 | A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane… | GlaxoSmithKline | Not Yet Recruiting | 2026-06-12 |
| NCT02201992 | Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has… | ECOG-ACRIN Cancer Research Group | Active, Not Recruiting | 2025-12-19 |
Cairo University (9) · Riphah International University (9) · VA Office of Research and Development (9) · Memorial Sloan Kettering Cancer Center (8) · M.D. Anderson Cancer Center (7) · Alkermes, Inc. (6) · Pfizer (6) · Shanghai Pulmonary Hospital, Shanghai, China (6) · Guangdong Association of Clinical Trials (5) · Hacettepe University (5)